uniQure (NASDAQ:QURE) Shares Pass Above 50 Day Moving Average – Time to Sell?

uniQure N.V. (NASDAQ:QURE)’s share price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $35.02 and traded as high as $41.92. uniQure shares last traded at $39.70, with a volume of 1,070,189 shares changing hands.

Wall Street Analyst Weigh In

QURE has been the subject of a number of recent research reports. Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $25.00 to $65.00 in a research note on Thursday, June 18th. HC Wainwright upped their price objective on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a report on Monday, June 29th. Chardan Capital increased their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Mizuho lifted their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

uniQure Price Performance

The business’s 50-day moving average price is $35.02 and its 200 day moving average price is $25.23. The company has a market capitalization of $2.50 billion, a P/E ratio of -11.41 and a beta of 0.90. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. Analysts anticipate that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Insider Activity

In other news, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider owned 108,864 shares in the company, valued at $2,945,859.84. This trade represents a 12.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 433,229 shares of company stock worth $17,944,799. Company insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently modified their holdings of QURE. Torren Management LLC bought a new position in shares of uniQure in the fourth quarter worth approximately $28,000. IFP Advisors Inc purchased a new position in uniQure in the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC purchased a new position in uniQure in the 4th quarter worth approximately $48,000. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the 3rd quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after buying an additional 906 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.